Anteris Advances PARADIGM Trial as Quarterly Cash Outflow Reaches US$23 Million
AVR: $8.50 +0.00% · MC: $876M
Anteris reported net operating cash outflows of approximately US$23 million for the September quarter, mainly supporting clinical, regulatory and manufacturing work on its PARADIGM trial. Trial enrolment is progressing across active sites, with regulatory clearance and approvals after quarter-end extending the study into Germany and Australia; the company also took occupancy of a Minnesota facility intended to expand production capacity ahead of potential commercialisation.

Comments